Securities code: Sichuan Kelun Pharmaceutical Co.Ltd(002422) securities abbreviation: Sichuan Kelun Pharmaceutical Co.Ltd(002422) Announcement No.: 2022026 Sichuan Kelun Pharmaceutical Co.Ltd(002422)
Announcement on the issuance results of public issuance of convertible corporate bonds
Sponsor (lead underwriter): Changjiang Securities Company Limited(000783) underwriting sponsor Co., Ltd
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Sichuan Kelun Pharmaceutical Co.Ltd(002422) (hereinafter referred to as ” Sichuan Kelun Pharmaceutical Co.Ltd(002422) ,” issuer “or” company “) has obtained the approval of China Securities Regulatory Commission (CSRC) in zjxk [2022] No. 255 for the public issuance of convertible corporate bonds (hereinafter referred to as” convertible bonds “or” Kelun convertible bonds “) Changjiang Securities Company Limited(000783) underwriting sponsor Co., Ltd. (hereinafter referred to as “Changjiang sponsor” or “sponsor (lead underwriter)”) is the sponsor (lead underwriter) of this offering. The convertible bonds issued this time are referred to as “Kelun convertible bonds” for short, and the bond code is “127058”. The scale of the convertible bonds issued this time is 300 million yuan, with a face value of 100 yuan each, a total of 30 million, which are issued at face value. The convertible bonds issued this time shall be placed preferentially to the original shareholders registered by China Securities Depository and Clearing Co., Ltd. Shenzhen Branch (hereinafter referred to as “CSDCC Shenzhen Branch”) after the closing of the market on the equity registration date (March 17, 2022, t-1), The balance after the preferential placement of the original shareholders (including the part that the original shareholders give up the preferential placement) is issued to the public investors online through the trading system of Shenzhen Stock Exchange (hereinafter referred to as “Shenzhen Stock Exchange”).
1、 The result of the preferential placement of convertible bonds by the original shareholders
The payment for the preferential placement of the original shareholders of this issuance has been completed on March 18, 2022 (t day). The original shareholders of this issuance gave priority to placing 24062119 pieces of Kelun convertible bonds, totaling 240621190000 yuan, accounting for 80.21% of the total amount of this issuance.
2、 Online subscription results of convertible bonds
Online of the balance after the preferential placement of the original shareholders (including the preferential placement abandoned by the original shareholders) in this issuance
The subscription and payment work has been completed on March 22, 2022 (T + 2). The sponsor (lead underwriter) made statistics on the final subscription of this online issuance of convertible bonds according to the data provided by Shenzhen Stock Exchange and China Clearing Shenzhen Branch. The results are as follows:
1. Number of convertible bonds subscribed by online investors (piece): 5864531
2. Subscription amount paid by online investors (yuan): 58645310000
3. Number of convertible bonds that online investors give up subscription (piece): 73349
4. Amount of subscription abandoned by online investors (yuan): 733490000
3、 Underwriting by the recommendation institution (lead underwriter)
According to the underwriting agreement, the convertible bonds that the online investors give up the subscription and the convertible bonds that are invalid due to insufficient funds of the settlement participants shall be underwritten by the sponsor (lead underwriter). In addition, the announcement on the issuance of Sichuan Kelun Pharmaceutical Co.Ltd(002422) public issuance of convertible corporate bonds stipulates that each one of them will be preferentially allotted to the original shareholders as one subscription unit, and every 10 online subscriptions will be one subscription unit. Therefore, one issuance balance will be underwritten by the sponsor (lead underwriter). The total number of underwriting by the recommendation institution (lead underwriter) is 73350, the underwriting amount is 733500000 yuan, and the underwriting proportion is 0.24%.
On March 24, 2022 (T + 4), the recommendation institution (lead underwriter) will transfer the underwriting funds together with the funds paid and subscribed by investors deducting the recommendation and underwriting expenses to the issuer according to the underwriting agreement. The issuer will submit the bond registration application to CSDCC Shenzhen Branch and register the underwritten convertible bonds to the securities account designated by the recommendation institution (lead underwriter).
4、 Contact information of sponsor (lead underwriter)
If investors have any questions about the issuance results announced in this announcement, please contact the sponsor (lead underwriter) of this issuance. The specific contact information is as follows:
Sponsor (lead underwriter): Changjiang Securities Company Limited(000783) underwriting sponsor Co., Ltd
Tel.: 02161118537
Contact: capital market department
Issuer: Sichuan Kelun Pharmaceutical Co.Ltd(002422) sponsor (lead underwriter): Changjiang Securities Company Limited(000783) underwriting sponsor Co., Ltd. March 24, 2022 (this page has no text and is the seal page of the announcement on the issuance results of Sichuan Kelun Pharmaceutical Co.Ltd(002422) public issuance of convertible corporate bonds)
Issuer: Sichuan Kelun Pharmaceutical Co.Ltd(002422) mm / DD / yyyy (this page has no text and is the seal page of the announcement on the issuance results of Sichuan Kelun Pharmaceutical Co.Ltd(002422) public issuance of convertible corporate bonds)
Sponsor (lead underwriter): Changjiang Securities Company Limited(000783) underwriting sponsor Co., Ltd. mm / DD / yyyy
